List view / Grid view
Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.
In this In-Depth Focus: realising the promise of laboratory automation in biomedical research, drug discovery from the age of information to the age of intelligence, and transforming drug discovery, development and delivery with flow chemistry.
In this In-Depth Focus: AI-driven automated chemistry as a tool to accelerate drug discovery, and a look at network-driven drug discovery
In this issue: AI-driven automated chemistry as a tool to accelerate drug discovery processes, the shifting landscape of immuno-oncology, and how lipid molecules provide an insight into biological research.
Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…
A machine-learning model has been developed to analyse protein sequences, giving an insight to their structure, function and phylogeny...
A team of researchers have developed a computational bioinformatic method to predict and accurately locate enhancer regions on cell lines.
Learn everything you need to know about the most widely-used mouse in biomedical research with this free whitepaper.
Artificial Intelligence has been used to cost-effectively diagnose diabetic-related eye disease automatically with far more accuracy than current methods...
Learn how the continued development of CRISPR gene editing technologies opens fresh possibilities for in vivo model design.
Machine learning could, in future, be the way that clinicians decide on particular courses of treatments for patients affected by cancer...
Discovery based on analysis of tissue and saliva samples from oral cancer patients shows a correlation between a signature comprising three peptides and the presence of lymph node metastasis...
Researchers are always looking more effective and efficient ways of making their work more successful. In this supplement, some of our commercial partners share their data, detailing the application of their technology.
Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.
The Blue Brain 3D atlas could be the future of analysing all cells in the brain, with high quality, high resolution images that can navigate the brain...
